• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RBM25 在肝细胞癌中预后性剪接调控网络。

Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma.

机构信息

Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

Bioengineered. 2021 Dec;12(1):1202-1211. doi: 10.1080/21655979.2021.1908812.

DOI:10.1080/21655979.2021.1908812
PMID:33830865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8806338/
Abstract

RNA-binding motif protein 25 (RBM25) is a poorly characterized RNA-binding protein that is involved in several biological processes and regulates the proliferation and metastasis of tumor cells. The regulatory role of RBM25 in hepatocellular carcinoma (HCC) is unknown. Here, RBM25 expression and outcomes in HCC patients were evaluated using The Cancer Genome Atlas database. RBM25 was overexpressed in HCC patients compared with the healthy group. The high expression of RBM25 in tumor tissues was significantly related to poor overall survival (P<0.001). Overexpression of RBM25 significantly contributed to poorer survival in male patients and N0 stage patients (P<0.001). Spearman analysis and weighted gene co-expression network analysis identified 694 RBM25-related genes. Protein-protein interaction network analysis revealed the Cluster with the highest score, which positively correlated with RBM25. CDCA5 and INCENP were identified as the core functional genes related to RBM25. The overexpression of CDCA5 and INCENP in HCC patients was examined using the Human Protein Atlas database. The findings collectively indicated that RBM25 may interact with CDCA5 and INCENP to regulate HCC. Our detailed characterization of RBM25 protein interactions and related core functional genes provides a basis for further studies aimed at identifying molecular regulatory pathways or splicing events.

摘要

RNA 结合基序蛋白 25(RBM25)是一种特征尚不明确的 RNA 结合蛋白,涉及多种生物学过程,并调节肿瘤细胞的增殖和转移。RBM25 在肝细胞癌(HCC)中的调节作用尚不清楚。本研究利用癌症基因组图谱数据库评估了 RBM25 在 HCC 患者中的表达和结局。与健康组相比,HCC 患者中 RBM25 的表达升高。肿瘤组织中 RBM25 的高表达与总生存期不良显著相关(P<0.001)。RBM25 的过表达与男性患者和 N0 期患者的生存率较差显著相关(P<0.001)。Spearman 分析和加权基因共表达网络分析鉴定出 694 个 RBM25 相关基因。蛋白质-蛋白质相互作用网络分析显示,得分最高的 Cluster 与 RBM25 呈正相关。CDCA5 和 INCENP 被鉴定为与 RBM25 相关的核心功能基因。使用人类蛋白质图谱数据库检测了 HCC 患者中 CDCA5 和 INCENP 的过表达情况。这些结果表明,RBM25 可能与 CDCA5 和 INCENP 相互作用以调节 HCC。我们对 RBM25 蛋白相互作用和相关核心功能基因的详细表征为进一步研究确定分子调控途径或剪接事件提供了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17d1/8806338/191299e9a48d/KBIE_A_1908812_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17d1/8806338/090c33c8a567/KBIE_A_1908812_UF0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17d1/8806338/58474934c1d3/KBIE_A_1908812_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17d1/8806338/d29ac0c921ea/KBIE_A_1908812_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17d1/8806338/7a02acc80d92/KBIE_A_1908812_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17d1/8806338/191299e9a48d/KBIE_A_1908812_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17d1/8806338/090c33c8a567/KBIE_A_1908812_UF0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17d1/8806338/58474934c1d3/KBIE_A_1908812_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17d1/8806338/d29ac0c921ea/KBIE_A_1908812_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17d1/8806338/7a02acc80d92/KBIE_A_1908812_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17d1/8806338/191299e9a48d/KBIE_A_1908812_F0004_OC.jpg

相似文献

1
Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma.RBM25 在肝细胞癌中预后性剪接调控网络。
Bioengineered. 2021 Dec;12(1):1202-1211. doi: 10.1080/21655979.2021.1908812.
2
CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC).CDCA5 过表达是肝细胞癌(HCC)患者预后不良的指标。
BMC Cancer. 2018 Nov 29;18(1):1187. doi: 10.1186/s12885-018-5072-4.
3
Overexpression of , , , and Coregulated Cell Cycle and Promoted Hepatocellular Carcinoma Development.过表达 、 、 、 和 共同调控细胞周期并促进肝细胞癌的发展。
J Comput Biol. 2020 Jun;27(6):965-974. doi: 10.1089/cmb.2019.0254. Epub 2019 Oct 9.
4
Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.CDCA5 沉默抑制癌症进展,并作为肝细胞癌的预后生物标志物。
Oncol Rep. 2018 Oct;40(4):1875-1884. doi: 10.3892/or.2018.6579. Epub 2018 Jul 17.
5
Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma.细胞分裂周期相关蛋白 5 表达水平升高预示着肝细胞癌患者的生存预后较差。
Aging (Albany NY). 2020 Jul 21;12(14):14542-14555. doi: 10.18632/aging.103501.
6
RBM25 depletion suppresses the growth of colon cancer cells through regulating alternative splicing of MNK2.RBM25 缺失通过调节 MNK2 的可变剪接抑制结肠癌细胞的生长。
Sci China Life Sci. 2024 Oct;67(10):2186-2197. doi: 10.1007/s11427-023-2582-x. Epub 2024 Aug 2.
7
High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.PARD3 高表达预示着肝癌预后不良。
Sci Rep. 2021 May 26;11(1):11078. doi: 10.1038/s41598-021-90507-w.
8
A Preliminary Investigation of PVT1 on the Effect and Mechanisms of Hepatocellular Carcinoma: Evidence from Clinical Data, a Meta-Analysis of 840 Cases, and In Vivo Validation.PVT1对肝细胞癌作用及机制的初步研究:来自临床数据、840例病例的荟萃分析及体内验证的证据
Cell Physiol Biochem. 2018;47(6):2216-2232. doi: 10.1159/000491534. Epub 2018 Jul 5.
9
Profiles of prognostic alternative splicing signature in hepatocellular carcinoma.肝癌中预后替代剪接特征的分析。
Cancer Med. 2020 Mar;9(6):2171-2180. doi: 10.1002/cam4.2875. Epub 2020 Jan 24.
10
Integrative analysis reveals the prognostic value and functions of splicing factors implicated in hepatocellular carcinoma.综合分析揭示了剪接因子在肝细胞癌中的预后价值和功能。
Sci Rep. 2021 Jul 26;11(1):15175. doi: 10.1038/s41598-021-94701-8.

引用本文的文献

1
Construction and validation of a post-translational modification-related signature to predict the effect of immune therapies in gastric cancer.用于预测免疫治疗在胃癌中疗效的翻译后修饰相关特征的构建与验证
Biochem Biophys Rep. 2025 Jul 14;43:102146. doi: 10.1016/j.bbrep.2025.102146. eCollection 2025 Sep.
2
Host factor RBM25 promotes HBV replication through Yin Yang 1-mediated cccDNA transcription.宿主因子RBM25通过阴阳1介导的cccDNA转录促进乙肝病毒复制。
Virol Sin. 2025 Jun;40(3):374-387. doi: 10.1016/j.virs.2025.05.004. Epub 2025 May 22.
3
Key oncogenes and candidate drugs for hepatitis-B-driven hepatocellular carcinoma progression.

本文引用的文献

1
CircCNTNAP3-TP53-positive feedback loop suppresses malignant progression of esophageal squamous cell carcinoma.环状衔接蛋白 3-TP53 正反馈回路抑制食管鳞状细胞癌的恶性进展。
Cell Death Dis. 2020 Nov 25;11(11):1010. doi: 10.1038/s41419-020-03217-y.
2
Proteome Analyses Reveal S100A11, S100P, and RBM25 Are Tumor Biomarkers in Colorectal Cancer.蛋白质组分析显示 S100A11、S100P 和 RBM25 是结直肠癌的肿瘤标志物。
Proteomics Clin Appl. 2021 Jan;15(1):e2000056. doi: 10.1002/prca.202000056. Epub 2020 Nov 6.
3
Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma.
乙型肝炎驱动的肝细胞癌进展的关键癌基因和候选药物。
Discov Oncol. 2025 Feb 4;16(1):116. doi: 10.1007/s12672-025-01851-6.
4
Role of ADAM33 short isoform as a tumor suppressor in the pathogenesis of thyroid cancer via oncogenic function disruption of full-length ADAM33.ADAM33 短异构体作为抑癌基因在甲状腺癌发病机制中的作用,通过破坏全长 ADAM33 的致癌功能。
Hum Cell. 2023 Jul;36(4):1451-1463. doi: 10.1007/s13577-023-00898-3. Epub 2023 Mar 28.
5
Metformin attenuates multiple myeloma cell proliferation and encourages apoptosis by suppressing METTL3-mediated m6A methylation of THRAP3, RBM25, and USP4.二甲双胍通过抑制 METTL3 介导的 THRAP3、RBM25 和 USP4 的 m6A 甲基化来抑制多发性骨髓瘤细胞增殖并促进细胞凋亡。
Cell Cycle. 2023 Apr;22(8):986-1004. doi: 10.1080/15384101.2023.2170521. Epub 2023 Feb 10.
6
Increased expression of SRPK1 (serine/arginine-rich protein-specific kinase 1) is associated with progression and unfavorable prognosis in cervical squamous cell carcinoma.SRPK1(丝氨酸/精氨酸丰富蛋白特异性激酶 1)的表达增加与宫颈鳞状细胞癌的进展和不良预后相关。
Bioengineered. 2022 Mar;13(3):6100-6112. doi: 10.1080/21655979.2022.2034705.
细胞分裂周期相关蛋白 5 表达水平升高预示着肝细胞癌患者的生存预后较差。
Aging (Albany NY). 2020 Jul 21;12(14):14542-14555. doi: 10.18632/aging.103501.
4
Roles and mechanisms of alternative splicing in cancer - implications for care.剪接在癌症中的作用和机制——对治疗的影响。
Nat Rev Clin Oncol. 2020 Aug;17(8):457-474. doi: 10.1038/s41571-020-0350-x. Epub 2020 Apr 17.
5
STAT1-induced upregulation of lncRNA RHPN1-AS1 predicts a poor prognosis of hepatocellular carcinoma and contributes to tumor progression via the miR-485/CDCA5 axis.STAT1诱导的lncRNA RHPN1-AS1上调预示着肝细胞癌的不良预后,并通过miR-485/CDCA5轴促进肿瘤进展。
J Cell Biochem. 2020 Dec;121(12):4741-4755. doi: 10.1002/jcb.29689. Epub 2020 Feb 17.
6
Exploration and validation of downregulated microRNA-199a-3p, downstream messenger RNA targets and transcriptional regulation in osteosarcoma.骨肉瘤中下调的微小RNA-199a-3p、下游信使核糖核酸靶点及转录调控的探索与验证
Am J Transl Res. 2019 Dec 15;11(12):7538-7554. eCollection 2019.
7
Tumour evolution in hepatocellular carcinoma.肝细胞癌中的肿瘤演进。
Nat Rev Gastroenterol Hepatol. 2020 Mar;17(3):139-152. doi: 10.1038/s41575-019-0229-4. Epub 2019 Dec 2.
8
Re: Dysregulation of p53-RBM25-Mediated circAMOTL1L Biogenesis Contributes to Prostate Cancer Progression through the circAMOTL1L-miR-193a-5p-Pcdha Pathway.回复:p53-RBM25介导的circAMOTL1L生物合成失调通过circAMOTL1L-miR-193a-5p-Pcdha途径促进前列腺癌进展。
J Urol. 2020 Feb;203(2):256-257. doi: 10.1097/01.JU.0000613432.22169.0b. Epub 2019 Nov 4.
9
Targeting the Chromosomal Passenger Complex Subunit INCENP Induces Polyploidization, Apoptosis, and Senescence in Neuroblastoma.靶向染色体乘客复合物亚单位 INCENP 诱导神经母细胞瘤多倍体形成、凋亡和衰老。
Cancer Res. 2019 Oct 1;79(19):4937-4950. doi: 10.1158/0008-5472.CAN-19-0695. Epub 2019 Aug 15.
10
CDCA5, Transcribed by E2F1, Promotes Oncogenesis by Enhancing Cell Proliferation and Inhibiting Apoptosis via the AKT Pathway in Hepatocellular Carcinoma.由E2F1转录的CDCA5通过激活AKT信号通路促进细胞增殖、抑制细胞凋亡,进而促进肝癌发生发展。
J Cancer. 2019 Apr 21;10(8):1846-1854. doi: 10.7150/jca.28809. eCollection 2019.